Generics

R&D

Competition is on the horizon for costly narcolepsy treatmen...

People who live with narcolepsy — about one out of every 2,000 Americans — don’t have many options when it comes to treatment.

News

NGOs claim UK-India free trade deal will raise medicine pric...

Consumer and health organisations in the UK have written to the Trade Secretary Kemi Badenoch, saying a leaked chapter of the proposed UK-India free trade agreement (FTA) could raise the pr

News

Medicines Patent Pool, Novartis pen deal to boost access to ...

The Medicines Patent Pool (MPP) and Novartis have unveiled a new

Spotlight on

Spotlight on the future of generics

Generic drugs play a vital role in ensuring affordable access to healthcare and the future sustainability of medicines development.

News

Novartis decides Sandoz' future – and it's a spin-out

After months of deliberation, and no formal offers from a buyer, Novartis has decided that its generics business Sandoz will be spun out into an independent company.

R&D

Challenges and opportunities in the off-patent sector: the p...

In the newest episode of the pharmaphorum podcast, editor-in-chief Jonah Comstock welcomes Rebecca Guntern, vice president of medicines for Europe at Sandoz.

Competition is on the horizon for costly narcolepsy treatmen...

NGOs claim UK-India free trade deal will raise medicine pric...

Medicines Patent Pool, Novartis pen deal to boost access to ...

Spotlight on the future of generics

Novartis decides Sandoz' future – and it's a spin-out

Challenges and opportunities in the off-patent sector: the p...

Setback for MSD as German court blocks Keytruda SC launch

How to meet your physicians where they are online

Generics

Editor's Picks